GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq:GNVC - News) announced today encouraging early results of a Phase II study with TNFerade™ in patients with locally advanced rectal cancer. The findings were presented yesterday in a poster session at the 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Los Angeles by Dr. Bronwyn Stall, Radiation Oncology Branch, National Cancer Institute, which is conducting the trial.
